We help leading organizations provide effective non-drug options for mental health

With our digital treatments, employers and health plans can lower health care costs, deliver meaningful clinical outcomes, and improve lives.

It’s no secret:
Mental health conditions are common, costly, and have far-reaching consequences


of people experience a mental health condition in their lifetime.1


When people don’t have access to mental health care, their employers can spend up to 300% more on health care costs.2


of adults with a mental health condition do not get care.3

Trusted by the world’s leading organizations

For nearly a decade, we’ve been empowering employers and health plans to help millions back to good mental health.

Simple to adopt, low-lift engagement

Add coverage to your
pharmacy plan

Pre-approved by major pharmacy benefit managers, add coverage in as few as 10 days.

Offer access via existing care pathways

Easily reach members when they need it.

Bill via pharmacy invoice 

Deep integrations mean you get to bill for therapeutic use via your pharmacy invoice.

Mental health care with proven outcomes and cost savings

Outcomes reporting

Receive data on improvements in clinical outcomes including sleep, anxiety, stress, and productivity.

Near-term ROI

Sleepio has been shown to impact health care spending with cost-effectiveness increasing over time.4

High engagement

Reach 30-40% of your population within the first year with optional custom communication support.

Custom population engagement strategies,
white-glove customer experience

For the past decade, we’ve been helping large organizations tackle mental health stigma and access barriers with custom-built engagement strategies. From nurses to truck drivers to members working from home or abroad, we’ve got you covered.

Image depicting various employee communication campaign materials, including "What's your Sleep Score?" campaign for Sleepio and advertisements for Daylight.

Supporting practicing clinicians

Partner with us to provide your patients with accessible, non-drug treatments for their mental health conditions.

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively. Users are directed to not make any changes to their prescribed medication or other type of medical treatment without seeking professional medical advice.

1. Kessler, R. C., Aguilar-Gaxiola, S., Alonso, J., Chatterji, S., Lee, S., Ormel, J., … & Wang, P. S. (2009). The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiology and Psychiatric Sciences, 18(1), 23-33.
2. Trzcinski, A. (2021, March 15). Forrester. Retrieved from: https://www.forrester.com/report/Invest+Now+Build+A+Resilient+Workforce+By+Prioritizing+Employee+Mental+Health/RES164922
3. Substance Abuse and Mental Health Services Administration. (2020). Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/.
4. Darden, M., Espie, C. A., Carl, J. R., Henry, A. L., Kanady, J. C., Krystal, A. D., & Miller, C. B. (2021). Cost-effectiveness of digital cognitive behavioral therapy (Sleepio) for insomnia: a Markov simulation model in the United States. Sleep, 44(4).

DOC-3045 Effective 07/2023